Boston Scientific logo

Boston Scientific (BSX) Q1 2026 Earnings

BSX·Reported April 22, 2026·Before market open

Boston Scientific reported Q1 2026 revenue of $5.2B (+11.6% YoY), beat analyst consensus of $5.2B by $30.1M. Diluted EPS came in at $0.80 (+6.7% YoY), beat the $0.79 consensus by $0.01. Boston Scientific reports across 2 business segments, led by Cardiovascular and MedSurg.

Revenue
$5.2Bbeat by $30.1M
Consensus: $5.2B
Diluted EPS
$0.80beat by $0.01
Consensus: $0.79
SEC

SEC Filings

Earnings release8-K · 0000885725-26-000031
Quarterly report10-Q / 10-K not filed yet

Q1 2026 Earnings FAQ

Common questions about Boston Scientific's Q1 2026 earnings report.

Boston Scientific (BSX) reported Q1 2026 earnings on April 22, 2026 before market open.

Boston Scientific reported revenue of $5.2B and diluted EPS of $0.80 for Q1 2026.

Revenue beat the consensus estimate of $5.2B by $30.1M. EPS beat the consensus estimate of $0.79 by $0.01.

Compared to the same quarter a year prior, revenue grew 11.6% from $4.7B a year earlier and diluted EPS grew 6.7% from $0.75.

You can read the 8-K earnings release (0000885725-26-000031) directly on SEC EDGAR. The filing index links above go to sec.gov.